Cytokine Growth Factor Rev . The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy

[tetano]

Cytokine Growth Factor Rev


. 2020 Dec 13;S1359-6101(20)30238-0.
doi: 10.1016/j.cytogfr.2020.12.001. Online ahead of print.
The roles and potential therapeutic implications of C5a in the pathogenesis of COVID-19-associated coagulopathy


Jing Li[SUP] 1 [/SUP], Bin Liu[SUP] 2 [/SUP]



Affiliations

• PMID: 33558131
• DOI: 10.1016/j.cytogfr.2020.12.001

Abstract

Emerging evidence has documented that multisystem organ failure in coronavirus disease 2019 (COVID-19) patients is strongly associated with various coagulopathies. Treatments for COVID-19-associated coagulopathy are still a clinical challenge. An advancement in the knowledge of mechanisms of the excessive or inappropriate activation of the complement cascade involved in the genesis of COVID-19-associated coagulopathy might be a fundamental approach for developing novel classes of anticoagulant drugs. In this context, there is emerging evidence indicating that C5a, a component of the complement system, and its receptors (C5aRs) play a critical role in the genesis of the COVID-19-associated hypercoagulable state. Thus, this review describes the mechanisms by which C5a/C5aR signaling participates in the cascade of events involved in the pathophysiology of COVID-19-associated coagulopathy. Furthermore, it highlights the current possibilities for the development of a novel therapeutic approach for COVID-19 patients that targets C5a/C5aRs signaling.

Keywords: Anaphylatoxin C5a; COVID-19-associated coagulopathy; Complement system; Pathogenesis.